DeepMed Research

Sapitinib

Generic Name: Sapitinib

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₅ClFN_₅O_₃

CAS Number: 848942-61-0

Unique Ingredient Identifier: 3499328002

Background: Sapitinib has been used in trials studying the treatment and basic science of Neoplasms, Breast Cancer, Breast Neoplasms, Metastatic Cancer, and Metastatic Breast Cancer, among others.

Clinical Trials

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: AZD2014
Drug: Anthracyclines
Drug: MEDI4736
Drug: AZD4547
Drug: Taxanes
Drug: AZD5363
Drug: cyclophosphamide
Drug: DNA intercalators
Drug: AZD8931
Drug: Selumetinib
Drug: Methotrexate
Drug: vinca alkaloids
Drug: Vandetanib
Drug: Platinum based chemotherapies
Drug: Bicalutamide
Drug: Olaparib
Drug: Bevacizumab
Drug: Mitomycin C
Drug: Eribulin

First Posted Date: 2014-11-24

Last Posted Date: 2025-01-15

Lead Sponsor: UNICANCER

Target Recruit Count: 1460

Registration Number: NCT02299999

Locations: 🇫🇷
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France
🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷
Hopitaux Du Leman, Thonon-les-Bains, France

and more 21 locations

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Drug: Standard maintenance for squamous NSCLC
Drug: AZD2014
Drug: Durvalumab
Drug: AZD4547
Drug: Pemetrexed
Drug: AZD5363
Drug: AZD8931
Drug: Selumetinib
Drug: Vandetanib
Drug: savolitinib
Drug: Olaparib

First Posted Date: 2014-04-17

Last Posted Date: 2024-01-10

Lead Sponsor: UNICANCER

Target Recruit Count: 999

Registration Number: NCT02117167

Locations: 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Institut Paoli Calmettes, Marseille, France

and more 34 locations

Phase I/II Trial of Antagonism of HER in GI Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer
Recurrent Colorectal Cancer

Interventions: Drug: AZD8931
Drug: Irinotecan
Drug: Folinic Acid
Drug: Fluorouracil

First Posted Date: 2013-05-24

Last Posted Date: 2019-08-19

Lead Sponsor: University College, London

Target Recruit Count: 24

Registration Number: NCT01862003

Locations: 🇬🇧
University College London Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧
Barts Health NHS Trust, London, United Kingdom

and more 1 locations

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

Phase 2

Terminated

Conditions: Metastatic, Gastric or Gastro-oesophageal Junction, Cancer

Interventions: Drug: Placebo
Drug: AZD8931
Drug: Paclitaxel

First Posted Date: 2012-04-18

Last Posted Date: 2014-09-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 39

Registration Number: NCT01579578

Locations: 🇨🇳
Research Site, Taipei, Taiwan

A Study to Compare Two Different Tablet Formulations of AZD8931 in Healthy Males and Females

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: AZD8931

First Posted Date: 2011-04-07

Last Posted Date: 2011-07-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 26

Registration Number: NCT01330758

Locations: 🇬🇧
Research Site, London, United Kingdom

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

Phase 2

Terminated

Conditions: Neoplasms
Breast Neoplasms
Breast Cancer

Interventions: Drug: AZD8931
Drug: anastrozole
Drug: Placebo

First Posted Date: 2010-06-28

Last Posted Date: 2014-07-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 482

Registration Number: NCT01151215

Locations: 🇬🇧
Research Site, Wythenshawe, Manchester, United Kingdom

Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.

Phase 1

Completed

Conditions: Neoplasms
Breast Cancer
Metastatic Cancer

Interventions: Drug: AZD8931
Drug: Paclitaxel

First Posted Date: 2009-10-28

Last Posted Date: 2014-07-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 17

Registration Number: NCT01003158

Locations: 🇯🇵
Research Site, Osaka, Japan

Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)

Phase 1

Completed

Conditions: Neoplasms
Breast Cancer
Breast Neoplasms

Interventions: Drug: AZD8931
Drug: Paclitaxel
Drug: Placebo

First Posted Date: 2009-05-13

Last Posted Date: 2016-01-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 330

Registration Number: NCT00900627

Locations: 🇬🇧
Research Site, Surrey, United Kingdom

A Study to Determine the Effect of Food on the Pharmacokinetics of Oral AZD8931 Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: AZD8931

First Posted Date: 2009-04-10

Last Posted Date: 2009-10-23

Lead Sponsor: AstraZeneca

Target Recruit Count: 24

Registration Number: NCT00879346

Locations: 🇬🇧
Research Site, Alderley Park, Cheshire, United Kingdom

Study of AZD8931 in Patients With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Advanced Solid Malignancies

First Posted Date: 2008-03-17

Last Posted Date: 2013-03-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 41

Registration Number: NCT00637039

Locations: 🇷🇺
Research Site, St. Petersburg, Russian Federation

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy